{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060486","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.119352+00:00","generated_at":"2026-06-01T23:24:44.978900+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tivic Health reports Q1 net loss down 29% YoY; raises $4M in May offering","bullets":["Q1 revenue $334K (-11% YoY), net loss $1.5M vs $2.1M, operating expenses down 26%.","Gross margin improved to 50% from 30%; gross profit up 48% to $167K.","May 13 public offering: 4.71M shares + warrants at $0.85/share, gross $4M, net $3.5M.","Clinical study with Feinstein Institutes showed ncVNS induced autonomic and neurologic responses equivalent to implanted devices.","Launched ClearUP 2.0; exclusive distribution deal with top-10 distributor for Walmart, Target, Kroger."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060486","json":"https://secwatch.observer/filing/0000950170-24-060486.json","markdown":"https://secwatch.observer/filing/0000950170-24-060486.md","text":"https://secwatch.observer/filing/0000950170-24-060486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024060486/0000950170-24-060486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024060486/tivc-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:24:44.978900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b2acd45e71a576a8ec76d4262cf40cbdb8bfcdd","claim":"Valion Bio, Inc. reported first quarter 2024 results: revenue $334 thousand.","evidence_excerpt":"Revenue for Q1 2024 was $334 thousand, compared to $376 thousand for Q1 2023, a decrease of $42 thousand, or 11%, due reduced unit sales volume offset by increased selling price.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024060486/0000950170-24-060486-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"$334 thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}